The contractor shall perform the transfer, validation and qualification of bioanalytical methods for detection of cabotegravir and levonorgestrel in RAT and nonhuman primate plasma
Ended Awarded Last action
- Contract number
- 75N93022F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $680,219
Award facts
- Contract value 100% obligated
- $680,219.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $54,811 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $139,107 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $486,301 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order contract to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization based in Albuquerque, New Mexico, to perform transfer, validation, and qualification of bioanalytical methods for detection of cabotegravir and levonorgestrel in rat and nonhuman primate plasma. The contract, valued at $680,219.00, carries a cost-plus fixed fee pricing structure with an ultimate completion date of April 15, 2026. This work supports NIAID's mission to develop preventive and therapeutic strategies for infectious diseases, with cabotegravir and levonorgestrel being active pharmaceutical ingredients under investigation for long-acting HIV prevention. The award was issued without a small business set-aside designation.
This delivery order likely represents a task order issued against one of Lovelace's existing IDIQ contracts with NIAID, which totals $136.6 million for evaluation and testing services for vaccines and related products. Lovelace's established capabilities in preclinical research, analytical testing, and nonhuman primate studies make it well-positioned to execute the bioanalytical method development and validation work required for these pharmaceutical compounds. The organization's experience across multiple federal agencies and its sophisticated laboratory infrastructure in Albuquerque support complex analytical and preclinical research needs critical to the drug development and regulatory pathway.
Quick answers
Who was awarded contract 75N93022F00001?
75N93022F00001 was awarded to Lovelace Biomedical Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 15, 2021.
How much is contract 75N93022F00001 worth?
The government has obligated $680,219 on 75N93022F00001.
Is contract 75N93022F00001 an order under another contract?
Yes. 75N93022F00001 is a delivery order under 75N93022D00001, an indefinite delivery contract.
Was contract 75N93022F00001 competed?
The extent of competition for 75N93022F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award